Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
37 hedge funds and large institutions have $5.11M invested in Carisma Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.18% less ownership
Funds ownership: 14.7% → 12.53% (-2.2%)
30% less funds holding
Funds holding: 53 → 37 (-16)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
45% less capital invested
Capital invested by funds: $9.28M → $5.11M (-$4.17M)
89% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$595K |
| 2 |
Renaissance Technologies
New York
|
+$73K |
| 3 |
Two Sigma Investments
New York
|
+$37K |
| 4 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$16.2K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$354K |
| 2 |
BlackRock
New York
|
-$327K |
| 3 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$304K |
| 4 |
Jane Street
New York
|
-$243K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$161K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
New York State Common Retirement Fund
Albany,
New York
| – | -$322 | -212 | Closed |
|
|
OPTFSNA
52
Old Point Trust & Financial Services N A
Newport News,
Virginia
| – | -$190 | -125 | Closed |
|
|
SRCM
53
Signature Resources Capital Management
Newport Beach,
California
| – | -$21 | -14 | Closed |
|
CARM Hedge Fund Activity: Q3 2024 in Review
37 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2024, worth a combined $5.11M — down 45% from $9.28M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CARM and 2 opened new positions — a net loss of 16 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Barclays, adding an estimated $595K. The largest seller was Goldman Sachs, exiting entirely with an estimated $354K sold.
- 37 institutional investors held Carisma Therapeutics (CARM) as of Q3 2024, down from 53 in Q2 2024.
- Funds reported $5.11M of Carisma Therapeutics stock for Q3 2024, down 45% quarter-over-quarter.
- 2 funds opened new Carisma Therapeutics positions in Q3 2024 and 18 closed out, a net change of -16 holders.
- The largest Carisma Therapeutics buyer in Q3 2024 was Barclays, an estimated $595K added.
- The largest Carisma Therapeutics seller in Q3 2024 was Goldman Sachs, an estimated $354K sold.
Based on aggregated 13F filings for Q3 2024.